Sanofi-Synthelabo Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on April 22, 2004, reports on Sanofi-Synthelabo's financial performance for the first quarter of 2004 (ended March 31, 2004). The filing also details significant corporate developments regarding the ongoing public offer to acquire Aventis, including regulatory filings and divestiture agreements.
Key Financial Metrics
Revenue: Consolidated sales for Q1 2004 totaled 2,193 million euros, representing an 18.4% increase on a comparable basis and 11.9% on a reported basis. Developed sales (including alliance partner sales) reached 2,826 million euros, up 27.1% on a comparable basis.
Profitability and Margins: The filing does not provide specific net income, operating profit, or margin percentages for the quarter. Management forecasts an increase in earnings per share of approximately 15% for the full year 2004, barring major adverse events.
Cash Flow, Debt, and Liquidity: Specific cash flow, debt, or liquidity figures are not provided in this document. However, the company successfully completed the first round of syndication for a 12 billion euro credit facility to finance the Aventis offer.
Dividends: An interim dividend of 0.97 euros per share was announced for payment on May 5, 2004, toward a total proposed annual dividend of 1.02 euros for 2003.
Material Changes vs. Prior Period
- Geographic Growth: All regions showed double-digit growth on a comparable basis. The United States saw the highest growth at 34.2% (consolidated sales of 538 million euros), followed by the Rest of the World at 25.7% and Europe at 10.9%.
- Product Performance: The top 10 products accounted for 69.5% of consolidated sales, growing 26.5% on a comparable basis. Key drivers included:
- Plavix: Consolidated sales of 394 million euros (+39.2%); Developed sales grew 63.4%.
- Eloxatin: Consolidated sales of 256 million euros (+53.3%), driven by strong US growth (+75.0%).
- Xatral: Consolidated sales of 72 million euros (+50.0%).
- Ambien/Stilnox: Consolidated sales of 345 million euros (+16.6%).
- Currency Impact: A negative currency effect of 6.4 percentage points impacted reported growth, primarily due to the US dollar.
Guidance, Outlook, and Material Events
Outlook: Management confirmed 2004 forecasts, expecting consolidated sales growth on a comparable basis similar to 2003 levels. At an exchange rate of 1.25 USD/EUR, earnings per share are projected to increase by roughly 15% before exceptional items and goodwill amortization.
Strategic Developments (Aventis Offer):
- Filed notifications with European and U.S. anti-trust authorities.
- Opened the U.S. offer for Aventis on April 12, 2004.
- Secured a 12 billion euro credit facility.
- Agreed to divest Arixtra and Fraxiparine assets to GlaxoSmithKline for 453 million euros, conditional on the completion of the Aventis offer.
Product Pipeline and Regulatory:
- Eloxatin: Received full indication in Europe and FDA approval for first-line treatment of advanced colorectal cancer in the U.S.
- Dronedarone: Positive results announced for phase III studies regarding atrial fibrillation.
- Acomplia (Rimonabant): Positive study results presented regarding cardiovascular risk management.
- Japan: Established a local sales force and submitted Plavix for regulatory approval.
Risks: Forward-looking statements are subject to risks including the success of R&D programs, intellectual property protection, healthcare reimbursement reforms, and the ability to expand profitably in the U.S.
Investor Verification Checklist
- Verify the final terms and completion status of the Aventis acquisition offer.
- Confirm the regulatory approval status of the divestiture of Arixtra and Fraxiparine to GlaxoSmithKline.
- Monitor the impact of currency fluctuations on future reported earnings versus comparable growth.
- Review the full Form 20-F and Reference Document for detailed risk factors regarding U.S. market expansion and pricing reforms.
- Track the commercial launch progress of Uroxatral in the U.S. and Plavix in Japan.